Meningococcal Disease: Clinical Trials

8 trials for Meningococcal Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 8

Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B
4CMenB Vaccine - Prematurity, Vaccination
Phase 4CompletedSt George's, University of London1362017-08-012020-12-01
South Australian Meningococcal B Vaccine Herd Immunity Study
Licensed 4CMenB vaccine - Meningococcal Disease
Phase 4CompletedUniversity of Adelaide344892017-04-012019-07-02
Hepatitis B Vaccination in Infants
Menjugate, Menitorix, NeisVac-C - Meningococcal Disease, Pneumococcal Disease
Phase 4CompletedPublic Health England3002013-07-012020-10-01
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine - Meningococcal Disease
Phase 4CompletedNovartis Vaccines4652013-05-012014-08-15
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
MenACWY-CRM (Menveo) - Meningococcal Disease
Phase 4CompletedGlaxoSmithKline39482013-03-152018-09-21
Understanding the Immune Response to Two Different Meningitis Vaccines
MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis), 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) - Meningitis, Meningococcal Disease
Phase 4CompletedUniversity of Oxford202012-12-012026-05-04
Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children
Meningococcal (Groups A and C) Polysaccharide Vaccine - Meningococcal Disease, Meningitis
Phase 4CompletedSanofi Pasteur, a Sanofi Company6662011-08-012014-05-08
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Disease
Phase 4CompletedSanofi Pasteur, a Sanofi Company5382010-12-012014-11-14

Narrower conditions

Meningococcal Infections (8)  ·  Meningitis (4)  ·  Diphtheria (1)  ·  Hepatitis B (1)  ·  Pneumococcal Infections (1)  ·  Premature Birth (1)  ·  Tetanus (1)  ·  Toxemia (1)  ·  Whooping Cough (1)

Broader conditions

Bacterial Infections (8)  ·  Bacterial Infections and Mycoses (8)  ·  Gram-Negative Bacterial Infections (8)  ·  Infections (8)  ·  Neisseriaceae Infections (8)  ·  Nervous System Diseases (4)  ·  Neuroinflammatory Diseases (4)  ·  Actinomycetales Infections (1)  ·  Blood-Borne Infections (1)  ·  Bordetella Infections (1)  ·  Clostridium Infections (1)  ·  Communicable Diseases (1)  ·  Corynebacterium Infections (1)  ·  DNA Virus Infections (1)  ·  Digestive System Diseases (1)

Interventions

Meningococcal Vaccines (3)  ·  4CMenB vaccine (2)  ·  MenC-CRM vaccine (1)  ·  Polysaccharides (1)  ·  halofantrine (1)  ·  lactitol (1)

Sponsors

Sanofi Pasteur, a Sanofi Company (2)  ·  GlaxoSmithKline (1)  ·  Novartis Vaccines (1)  ·  Public Health England (1)  ·  St George's, University of London (1)  ·  University of Adelaide (1)  ·  University of Oxford (1)

Countries

United Kingdom (3)  ·  Australia (1)  ·  China (1)  ·  Philippines (1)  ·  South Korea (1)  ·  Ukraine (1)  ·  United States (1)

Top investigators

Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1)  ·  Elizabeth Coates, PhD (1)  ·  Helen Marshall (1)  ·  Paul Heath, MBBS (1)

Results publications

PMID 31634044, PMID 31971677, PMID 32447370, PMID 32712083, PMID 33587122, PMID 38234190, PMID 38977298, PMID 40652683

NIH funding

2017 (1)